12 hours ago
1
Sundry Photography/iStock Editorial via Getty Images
Merck (NYSE:MRK) is cutting $3 billion from its annual expenses as it prepares for generic competition to its blockbuster cancer drug, Keytruda.
The Rahway, New Jersey-based company announced Tuesday it will reduce administrative, sales, and research roles, and scale back its global real estate
English (US) ·